US FDA approves <a href="https://laohu8.com/S/JNJ">JNJ</a>'s blood cancer drug
March 5 (Reuters) - The U.S. Food and Drug Administration on Thursday approved Johnson & Johnson's JNJ.N treatment for a type of blood cancer, making it the third drug cleared under the agency's new speedy review program.
The health regulator approved the use of Tecvayli in combination with Darzalex in patients with myeloma who have received at least one prior line of therapy.
(Reporting by Sriparna Roy in Bengaluru; Editing by Alan Barona)
((Sriparna.Roy@thomsonreuters.com))
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments